OPKO Health Inc. on Friday said its weekly injection to treat growth hormone deficiency failed to achieve its primary goal compared with a placebo in a late-stage trial, sending shares sharply lower.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback